Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.

Autor:	Danese, Silvio1 (AUTHOR), Vermeire, Séverine2 (AUTHOR), Zhou, Wen3 (AUTHOR), Pangan, Aileen L3 (AUTHOR), Siffledeen, Jesse4 (AUTHOR), Greenbloom, Susan5 (AUTHOR), Hébuterne, Xavier6 (AUTHOR), D'Haens, Geert7 (AUTHOR), Nakase, Hiroshi8 (AUTHOR), Panés, Julian9 (AUTHOR), Higgins, Peter D R10 (AUTHOR), Juillerat, Pascal11 (AUTHOR), Lindsay, James O12 (AUTHOR), Loftus, Edward V Jr13 (AUTHOR), Sandborn, William J14 (AUTHOR), Reinisch, Walter15 (AUTHOR), Chen, Min-Hu16 (AUTHOR), Sanchez Gonzalez, Yuri3 (AUTHOR), Huang, Bidan3 (AUTHOR), Xie, Wangang3 (AUTHOR)
Zdroj:	Lancet. Jun2022, Vol. 399 Issue 10341, p2113-2128. 16p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu